Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data

AAPS Journal

Volumn 18, Issue 1, 2016, Pages 196-209

  Wendling, Thierry ^a,b   Tsamandouras, Nikolaos ^a   Dumitras, Swati ^b   Pigeolet, Etienne ^b   Ogungbenro, Kayode ^a   Aarons, Leon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bayesian population approach; mavoglurant; PBPK extrapolation; physiologically based pharmacokinetic models; proper lumping

Indexed keywords

MAVOGLURANT; INDOLE DERIVATIVE;

ADULT; ARTICLE; BAYES THEOREM; CHILD; CLINICAL STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MONTE CARLO METHOD; NORMAL HUMAN; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PROBABILITY; SINGLE DRUG DOSE; UNCERTAINTY; VOLUNTEER; ALGORITHM; BIOLOGICAL MODEL; BRAIN; COMPUTER SIMULATION; LIVER; MARKOV CHAIN; METABOLISM; PHARMACOKINETICS; POPULATION; PRESCHOOL CHILD; STATISTICAL MODEL;

ADULT; ALGORITHMS; BAYES THEOREM; BRAIN; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; HUMANS; INDOLES; LIVER; MARKOV CHAINS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; PHARMACOKINETICS; POPULATION;

EID: 84952976768     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9840-7     Document Type: Article

References (26)

1. Wakefield JC, Smith AFM. Bayesian analysis of linear and non-linear population models by using the Gibbs sampler. Appl Stat. 1994;43:201–21.
2. Gueorguieva I, Aarons L, Rowland M. Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS. J Pharmacokinet Pharmacodyn. 2006;33(5):571–94. doi:10.1007/s10928-006-9023-3.
3. Jonsson F, Jonsson EN, Bois FY, Marshall S. The application of a Bayesian approach to the analysis of a complex, mechanistically based model. J Biopharm Stat. 2007;17(1):65–92. doi:10.1080/10543400600851898.
4. Garcia RI, Ibrahim JG, Wambaugh JF, Kenyon EM, Setzer RW. Identifiability of PBPK models with applications to dimethylarsinic acid exposure. J Pharmacokinet Pharmacodyn. 2015. doi:10.1007/s10928-015-9424-2.
5. Okino MS, Mavrovouniotis ML. Simplification of mathematical models of chemical reaction systems. Chem Rev. 1998;98(2):391–408.
6. Wei J, Kuo JCW. Lumping analysis in monomolecular reaction systems. Analysis of the exactly lumpable system. Ind Eng Chem Fundam. 1969;8(1):114–23. doi:10.1021/i160029a019.
7. Dokoumetzidis A, Aarons L. Proper lumping in systems biology models. IET Syst Biol. 2009;3(1):40–51. doi:10.1049/iet-syb:20070055.
8. Dokoumetzidis A, Aarons L. A method for robust model order reduction in pharmacokinetics. J Pharmacokinet Pharmacodyn. 2009;36(6):613–28. doi:10.1007/s10928-009-9141-9.
9. Wendling T, Dumitras S, Ogungbenro K, Aarons L. Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics. J Pharmacokinet Pharmacodyn. 2015. doi:10.1007/s10928-015-9430-4.
10. Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. 2015;79(1):48–55. doi:10.1111/bcp.12234.
11. Walles M, Wolf T, Jin Y, Ritzau M, Leuthold LA, Krauser J, et al. Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos: Biol Chem. 2013;41(9):1626–41. doi:10.1124/dmd.112.050716.
12. Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett. 2001;120(1-3):411–20.
13. Wendling T, Ogungbenro K, Pigeolet E, Dumitras S, Woessner R, Aarons L. Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects. Pharm Res. 2015;32(5):1764–78. doi:10.1007/s11095-014-1574-1.
14. Yates JW. Structural identifiability of physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2006;33(4):421–39. doi:10.1007/s10928-006-9011-7.
15. Oehlert GW. A note on the delta method. Am Stat. 1992;46(1):27–9. doi:10.1080/00031305.1992.10475842.
16. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM users guide—part VIII. Hanover, MD: ICON Development Solutions; 2013.
17. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7(4):457–72. doi:10.2307/2246093.
18. Best NG, Cowles MK, Vines SK. CODA manual version 0.30. MRC Biostatistics Uni, Cambridge, UK. 1995.
19. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276(5309):122–6. doi:10.1126/science.276.5309.122.
20. Bois FY, Maszle DR. MCSim: a Monte Carlo simulation program. J Stat Softw. 1997;2(9):1–60.
21. Tsamandouras N, Wendling T, Rostami-Hodjegan A, Galetin A, Aarons L. Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations. J Pharmacokinet Pharmacodyn. 2015. doi:10.1007/s10928-015-9418-0.
22. Valentin J. Guide for the practical application of the ICRP human respiratory tract model. A report of ICRP supporting guidance 3: approved by ICRP committee 2 in october 2000. Ann ICRP. 2002;32(1-2):13–306.
23. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13(4):407–84.
24. Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401–31. doi:10.1007/s10928-007-9053-5.
25. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013–34. doi:10.2165/00003088-200645100-00005.
26. Gulati A, Isbister GK, Duffull SB. Scale reduction of a systems coagulation model with an application to modeling pharmacokinetic-pharmacodynamic data. CPT: Pharmacometrics Syst Pharmacol. 2014;3, e90. doi:10.1038/psp.2013.67.